ESR1 and breast cancer: Tamoxifen is a selective estrogen receptor modulator which reduces risk of estrogen receptor (ER)-positive breast cancer risk by 50% in the prevention setting for women at high breast cancer risk (e.g., based on the Gail model) [1] and lowers mortality by 30% in the adjuvant setting irrespective of grade [2].